Charles River, Valo Health create AI drug software

By The Science Advisory Board staff writers

April 28, 2022 -- Charles River Laboratories and Valo Health have launched Logica, an artificial intelligence (AI) powered drug discovery software application that creates a computation-powered, unified target-to-candidate offering.

Logica uses Valo's Opal computational platform and Charles River's preclinical expertise to provide advanceable leads and drug candidates with the goal of helping companies scale faster and make better drugs for their patients. The combined approaches have a demonstrated ability to produce an advanceable lead series 90% of the time and deliver development candidates 58% of the time, according to the firms.

Embedded in Logica are the exclusively available Logica Advanceable Lead (Logica-AL) and Candidate (Logica-C). Logica-AL provides information such as in vitro absorption, distribution, metabolism, and excretion, as well as selectivity profiles.

Logica-C uses the advanceable leads and trained predictive models to progress the program with the goal of delivering a development candidate that has undergone safety and efficacy tests and is ready for investigational new drug studies.

The software stems from a multiyear strategic partnership that Charles River and Valo announced in January.


Copyright © 2022 scienceboard.net
 

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:



Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences



Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.